Cresilon, Brooklyn, New York, United States: Bringing Life-Saving Innovation to Market

Written answers to the questions

Total 198 words used.

Cresilon is a Brooklyn-based biotech company on a mission to save lives with its proprietary plant-based gel technology that stops life-threatening bleeding in seconds. 

The company was launched in 2010 out of the dorm room of a 17-year-old bioengineering student who invented the first-of-its-kind hemostatic technology while attending New York University. Since then, Cresilon has raised more than $100 million in capital and grown to over 70 employees working at the only biomanufacturing facility of its kind in all of New York City. 

Last year, the company received its first FDA clearance for its innovative hemostatic technology in human use. Cresilon quickly followed this up by submitting an FDA application for TRAUMAGEL – and aims to bring the company’s revolutionary plant-based hemostatic gel to the trauma and emergency markets this year for the treatment of life-threatening bleeding.

As Cresilon advances towards saving human lives, the company and its core technology has already proven its impact by saving the lives of pets and animals. Cresilon's first commercial product, VETIGEL®, debuted in 2021 and is now being used by veterinarians around the world to treat pets during a wide range of surgical procedures and save animal lives in emergency situations. 

Total 245 words used.

In addition to Cresilon's first FDA clearance in human use for its proprietary plant-based gel technology that stops severe bleeding in seconds, the company achieved the following milestones:

• Formed a research and development agreement with the U.S. Defense Department's Walter Reed Army Institute of Research to study the company's hemostatic technology in the treatment of traumatic brain injuries.
• Advanced TRAUMAGEL to FDA submission while preparing for the product's launch in the trauma and emergency markets this year (pending FDA clearance).
• Cresilon's first-of-its-kind product on the animal health market, VETIGEL, is increasingly being utilized by licensed veterinarians worldwide and surpassed over 45,000 uses in surgical procedures worldwide.
• The company significantly expanded its global reach for VETIGEL by forming partnerships with all the leading distributors of veterinary products and services.
• Cresilon expanded its biomanufacturing operations to a total of 33,000 square feet at the company's state-of-the-art good manufacturing practices (GMP) facility in Brooklyn – which is the only biomanufacturing facility of its kind in all of New York City's five boroughs.
• Through the company's continued innovations and advancements with its proprietary plant-based gel technology, 100% of the algae is harvested from sustainable sources.
• Cresilon continues creating high-quality jobs of the future in New York City while attracting bright young talent through its annual summer internship program. The company's program, which collected more than 1,700 applicants from top universities around the world this year, provides college students with hands-on experience in the biotech industry.

Total 230 words used.

Every second counts during medical emergencies with life-threatening bleeding. Whether it's from a gunshot wound in combat or a massive intraoperative hemorrhage, severe blood loss can kill in a matter of minutes. These are just some of the medical emergencies and life-or-death situations Cresilon was founded for and its innovative hemostatic technology was designed for.

While there are many products currently on the market that stop bleeding, they all have several severe shortcomings, including: preparation and long wait times, lengthy periods of manual pressure, special storage conditions, can be difficult to apply, or not suited to work across all types of bleeds in external wounds.

Cresilon's first of its kind plant-based technology is designed to solve these critical issues by working instantaneously to stop all types of bleeds on contact in external wounds, from major trauma like gunshot wounds to highly precise surgical applications like tumor removal surgeries. The revolutionary hemostatic gel is supplied in a pre-filled syringe and provides an incredibly fast, effective, and easy-to-use solution designed to stop and control bleeding without the need for manual pressure, preparation, or special storage conditions.

Cresilon's mission is to save lives. In carrying out this mission with its medical miracle gel that stops severe bleeding in seconds, Cresilon is working to prevent deaths from uncontrolled trauma-related hemorrhage – which remains the primary preventable cause of death among those with critical injury.

Total 246 words used.

According to a report on the epidemiology of trauma-related hemorrhage: "Trauma claims the lives of more than four million people world-wide annually with uncontrolled hemorrhage being a primary cause of death among those injured. In the United States alone, trauma remains a leading cause of death for people of all ages, with the greatest impact on adults under the age of 45 and adolescents. Importantly, almost one-quarter of deaths due to uncontrolled hemorrhage may have been prevented."

For greater context and perspective on the implications of Cresilon and the company’s mission to save lives with its innovative plant-based gel technology that stops severe bleeding in seconds, consider these research reports and studies:

• A review in The New England Journal of Medicine estimates that each year, about 60,000 Americans die from hemorrhaging, or blood loss. Worldwide, that number is almost 2 million.
• According to the National Association of Emergency Medical Technicians' "Introduction to Tactical Combat Casualty Care," hemorrhage from extremity wounds is one of the three most common causes of preventable death on the battlefield.
• Post-surgical bleeding is associated with more deaths than blood clots from surgery, according to a Vanderbilt University Medical Center study published in the journal Anesthesia & Analgesia.

For additional information about Cresilon and supporting materials related to this nomination, please refer to the following feature stories reported by various media outlets in the past year: Spectrum NY1 News, News 12 Brooklyn, MedTech Dive, The MedTech Strategist, BioWorld, and dvm360.